HIGHLIGHTS
- who: Chen Lyu and collaborators from the Tumor Immunology Laboratory, LIFE Center, LMU Klinikum, University Munich, Planegg, Germany have published the Article: Identification of EZH2 as Cancer Stem Cell Marker in Clear Cell Renal Cell Carcinoma and the Anti-Tumor Effect of Epigallocatechin-3-Gallate (EGCG), in the Journal: Cancers 2022, 4200 of 17/04/2021
- what: In this study, the effect of EGCG on the expression of the CSC marker EZH2 and the corresponding biological functions were studied using ccRCC lines. The high prognostic value of EZH2 expression and its association with immune related . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.